Not finding it? Sign in to also search OpenAlex live.
-
LB0001 EFFICACY AND SAFETY OF DEUCRAVACITINIB UP TO WEEK 16 FROM POETYK PsA-1: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS2025 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
D. van der Heijde, P.J. Mease, C. Paul, F. Behrens, Laure Gossec, Yuichiro Kaneko, +15 more
4citations -
LB0010 INHIBITION OF STRUCTURAL DAMAGE PROGRESSION WITH GUSELKUMAB, A SELECTIVE IL-23i, IN PARTICIPANTS WITH ACTIVE PsA: RESULTS THROUGH WEEK 24 OF THE PHASE 3b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED APEX STUDY2025 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
P. J. Mease, Christopher T. Ritchlin, Laura C. Coates, A. Kollmeier, Bin Zhou, Y. Jiang, +4 more
3citations -
PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients2024 European Journal of Radiology article Medicine Prostate Cancer Treatment and Research Open access
Fleur Kleiburg, Lioe‐Fee de Geus‐Oei, Saskia A. C. Luelmo, Jelle J. Goeman, Frits Smit, Tom van der Hulle, +1 more
22citations -
Multiphasic68Ga-PSMA PET/CT in the Detection of Early Recurrence in Prostate Cancer Patients with a PSA Level of Less Than 1 ng/mL: A Prospective Study of 135 Patients2020 Journal of Nuclear Medicine article Medicine Prostate Cancer Diagnosis and Treatment Open access
Mohsen Beheshti, Reyhaneh Manafi‐Farid, Hans Geinitz, Reza Vali, Wolfgang C. Loidl, Felix Manuel Mottaghy, +1 more
43citations -
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial2026 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access
Désirée M F M van der Heijde, Philip J. Mease, Carle PAUL, Frank Behrens, Laure Gossec, Yuko Kaneko, +16 more
1citations -
Inhibition of structural damage progression with the selective interleukin-23 inhibitor guselkumab in participants with active PsA: results through week 24 of the phase 3b, randomised, double-blind, placebo-controlled APEX study2025 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, +6 more
10citations -
OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES2020 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access cited by 2 patents
Philip Helliwell, Dafna D. Gladman, Denis Poddubnyy, Philip J. Mease, Xenofon Baraliakos, Alexa P. Kollmeier, +9 more
14citations -
Procedural sedation and analgesia with propofol (PSA) for gynecologic surgery: A systematic review of the literature2023 European Journal of Obstetrics & Gynecology and Reproductive Biology review Medicine Anesthesia and Sedative Agents Open access
Julia F. van der Meulen, Janique R. J. Dreessen, S.F.P.J. Coppus, Helen S. Kok, Marlies Y. Bongers
7citations -
EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19 SUBUNIT OF IL-23, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-52 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES2021 Congresso Brasileiro de Reumatologia conference-paper Medicine Spondyloarthritis Studies and Treatments Open access
Rafael Tomaz Gomes, Philip Mease, Philip Helliwell, Dafna D. Gladman, Denis Poddubnyy, Désirée M F M van der Heijde, +12 more
2citations -
SAT0398 PERSISTENCE OF USTEKINUMAB (UST) OR TNF INHIBITOR (TNFI) TREATMENT IN PSORIATIC ARTHRITIS (PsA): INSIGHTS FROM THE LARGE, PROSPECTIVE, MULTINATIONAL, REAL-WORLD PsABio COHORT2020 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access
Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz E. Joven-Ibáñez, +6 more
2citations -
POS1037 EFFECT OF GUSELKUMAB, A SELECTIVE IL-23p19 INHIBITOR, ON AXIAL-RELATED ENDPOINTS IN PATIENTS WITH ACTIVE PsA: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS2022 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access
Philip J. Mease, P. S. Helliwell, D. D. Gladman, Denis Poddubnyy, Xenofon Baraliakos, Soumya D. Chakravarty, +6 more
2citations -
SAT0432 EFFECT OF SEX ON DISEASE CHARACTERISTICS AND DISEASE IMPACT IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA): INSIGHTS FROM THE REAL-WORLD, OBSERVATIONAL MULTINATIONAL PsABio COHORT2020 Annals of the Rheumatic Diseases article Medicine Spondyloarthritis Studies and Treatments Open access
Michael Twahier Nurmohamed, Irene E. van der Horst-Bruinsma, Arno W. van Kuijk, Stefan Siebert, Paul Bergmans, Kurt de Vlam, +8 more
2citations -
AB0898 Guselkumab improves dactylitis in PsA patients with inadequate response to TNFi: data from the Phase 3b COSMOS trial2022 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments Open access
Helena Marzo‐Ortega, E. Theander, M. Neuhold, P. Bergmans, M. Shawi, Michelle Perate, +3 more
0citations -
Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy2020 European Journal of Nuclear Medicine and Molecular Imaging article Medicine Prostate Cancer Diagnosis and Treatment Open access
Jonathan Miksch, Dirk Bottke, Thomas Krohn, Reinhard Thamm, Detlef Bartkowiak, Christoph Solbach, +5 more
46citations -
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study
Elizabeth Kathryn Bancroft, Elizabeth C. Page, Jana Kathlyn McHugh, Sarah Thomas, Natalie Taylor, Jennifer Pope, +94 more
5citations -
Personalised biopsy schedules based on risk of Gleason upgrading for patients with low‐risk prostate cancer on active surveillance2020 British Journal of Urology article Medicine Prostate Cancer Diagnosis and Treatment Open access
Anirudh Tomer, Daan Nieboer, Monique J. Roobol, Anders S Bjartell, Ewout Willem Steyerberg, Dimitris Rizopoulos
29citations -
A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE2021 International Journal of Cancer article Medicine Prostate Cancer Treatment and Research Open access
Heather Ann Payne, Angus Robinson, Bernard Rappe, Serena Hilman, Ugo De Giorgi, Steven Joniau, +13 more
18citations -
A nomogram to predict pathologic T2 stage in candidates to robot-assisted radical prostatectomy with iT3 prostate cancer on preoperative multiparametric MRI: results from a multi-institutional collaboration2022 Minerva Urology and Nephrology article Medicine Prostate Cancer Diagnosis and Treatment Open access
Carlo Andrea Bravi, Elio Mazzone, Paolo Dell’Oglio, Márcio Covas Moschovas, Alberto Martini, Giuseppe Rosiello, +14 more
7citations